Literature DB >> 16925685

Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.

Ko-Huang Lue1, Yung-Hsiang Lin, Hai-Lun Sun, Ko-Hsiu Lu, Jie-Cheng Hsieh, Ming-Chih Chou.   

Abstract

Immunotherapy through oral routes is thought to be a valuable therapeutic option for asthma. The clinical and immunologic effects of sublingual immunotherapy (SLIT) in children with asthma caused by mites were evaluated in a double-blind, placebo-controlled study for 6 months. Patients (aged 6-12 yr) with mild-to-moderate asthma, with single sensitization to mite allergen, received either SLIT or placebo with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f.) 50/50 extract. The cumulative dose was around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen. Symptom and medication scores were assessed throughout the study. Serum total immunoglobulin (Ig)E, eosinophil count, eosinophil cationic protein, specific IgE, specific IgG4, and skin sensitivity were evaluated before starting the treatment and after the treatment period. Twenty patients completed the study. At the beginning of the treatment, no differences were observed between the groups for symptom and medication scores, skin sensitivity, or immunologic parameters. After 6 months of treatment, there was a significant difference in nighttime asthma symptom scores and specific IgG4 (p < 0.05) in the SLIT group compared with the placebo group. Daytime symptom and medication scores, total IgE, eosinophil count, forced expiratory volume in 1 s, and mean evening peak expiratory flow rate reached significant differences in the SLIT group during the treatment period (p < 0.05). No severe adverse effects were reported. Our results revealed that treatment for 6 months with SLIT is clinically effective in decreasing asthmatic symptoms and medication use in children with mild-to-moderate asthma because of mite sensitivity. The clinical usefulness of this form of immunotherapy and the mechanism underlying its immunologic effects deserve further studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16925685     DOI: 10.1111/j.1399-3038.2006.00443.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  28 in total

Review 1.  New types of immunotherapy in children.

Authors:  Noel Rodríguez-Pérez; Martin Penagos; Jay M Portnoy
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

Review 2.  Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis.

Authors:  Ivana Đurić-Filipović; Marco Caminati; Gordana Kostić; Đorđe Filipović; Zorica Živković
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

Review 3.  Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review.

Authors:  Julia M Kim; Sandra Y Lin; Catalina Suarez-Cuervo; Yohalakshmi Chelladurai; Murugappan Ramanathan; Jodi B Segal; Nkiruka Erekosima
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

4.  Sub-lingual immunotherapy: world allergy organization position paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2009-11-19       Impact factor: 4.084

Review 5.  Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

Authors:  Jasper H Kappen; Stephen R Durham; Hans In 't Veen; Mohamed H Shamji
Journal:  Ther Adv Respir Dis       Date:  2016-09-27       Impact factor: 4.031

Review 6.  Particularities of allergy in the Tropics.

Authors:  Luis Caraballo; Josefina Zakzuk; Bee Wah Lee; Nathalie Acevedo; Jian Yi Soh; Mario Sánchez-Borges; Elham Hossny; Elizabeth García; Nelson Rosario; Ignacio Ansotegui; Leonardo Puerta; Jorge Sánchez; Victoria Cardona
Journal:  World Allergy Organ J       Date:  2016-06-27       Impact factor: 4.084

Review 7.  Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

Review 8.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

Review 9.  Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing, and efficacy.

Authors:  Désirée Larenas-Linnemann
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

10.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.